

bibkhv/3.2019

BIBLIOGRAPHY

Kirsi Vähäkangas, M.D., Ph.D., Professor of Toxicology (emer.)

A. ORIGINAL ARTICLES IN PEER-REVIEWED JOURNALS

- A1. Vähäkangas, K., Nevasaari, K., Pelkonen, O. and Kärki, N.T.: The metabolism of benzo(a)pyrene in isolated perfused lungs from variously-treated rats. *Acta pharmacol. et toxicol.* 41: 129-140, 1977.
- A2. Vähäkangas, K. and Pelkonen, O.: The effects of harman and norharman on the metabolism of benzo(a)pyrene in isolated perfused rat lung and in rat lung microsomes. *Biochem. Pharmacol.* 28: 1591-1596, 1979.
- A3. Vähäkangas, K., Nevasaari, K., Pelkonen, O. and Kärki, N.T.: Effects of various in vitro inhibitors of benzo(a)pyrene metabolism in isolated rat lung perfusion. *Acta Pharmacol. et Toxicol.* 24: 1-8, 1979.
- A4. Vähäkangas, K., Nebert, D.W. and Pelkonen, O.: The DNA binding of benzo(a)pyrene metabolites catalyzed by rat lung microsomes in vitro and in isolated perfused rat lung. *Chem.-Biol. Interact.* 24: 167-176, 1979.
- A5. Vähäkangas, K.: The distribution of benzo(a)pyrene and its metabolites in isolated perfused lung and liver. *Toxicol. Lett.* 4: 413-418, 1979.
- A6. Vähäkangas, K., Hirn, M. and Pelkonen, O.: Effect of maternal cigarette smoke exposure on fetuses of inbred strains of mice responsive and non-responsive to polycyclic aromatic hydrocarbons. *Toxicol. Lett.* 10: 81-86, 1982.
- A7. Raunio, H., Vähäkangas, K., Saarni, H. and Pelkonen, O.: Effects of cigarette smoke on rat lung and liver ornithine decarboxylase and aryl hydrocarbon hydroxylase activities and lung benzo(a)pyrene metabolism. *Acta Pharmacol. et Toxicol.* 52: 168-174, 1983.
- A8. Vähäkangas, K., Pelkonen, O. and Sotaniemi, E.: Cigarette smoking and drug metabolism. *Clin. Pharmacol. Ther.* 33: 375-380, 1983.
- A9. Dawson, J.R., Vähäkangas, K., Jernström, B. and Moldeus, P.: Glutathione conjugation by isolated lung cells and isolated, perfused lung. Effect of extracellular glutathione. *Eur. J. Biochem.* 138: 439-443, 1984.
- A10. Vähäkangas, K., Rajaniemi, H. and Pelkonen, O.: Ovarian toxicity of cigarette smoke exposure during pregnancy in mice. *Toxicol. Lett.* 25: 75-80, 1985.
- A11. Autrup, H., Wakhisi, J., Vähäkangas, K., Wasunna, O.A. and Harris, C.C.: Detection of 8,9-dihydro-(7'guanyl)-9-hydroxyafatoxin B1 in human urine. *Environ. Health Perspect.* 62: 105-108, 1985.

- A12. Vähäkangas, K., Trivers, G.E., Rowe, M. and Harris, C.C.: Benzo(a)pyrene diolepoxide-DNA adducts detected by synchronous fluorescence spectrophotometry. *Environ. Health Perspect.* 62: 101-104, 1985.
- A13. Vähäkangas, K., Haugen, Å. and Harris, C.C.: An applied synchronous fluorescence spectrophotometric assay to study benzo(a)pyrene diolepoxide-DNA adducts. *Carcinogenesis* 6: 1109-1116, 1985.
- A14. Harris, C.C., Vähäkangas, K., Newman, M.J., Trivers, G.E., Shamsuddin, A., Sinopoli, N., Mann, D.L. and Wright, W.E.: Detection of benzo(a)pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. *Proc. Natl. Acad. Sci. USA* 82: 6672-6676, 1985.
- A15. Haugen, Å., Becher, G., Benestad, C., Vähäkangas, K., Trivers, G.E., Newman, M. and Harris, C.C.: Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a)pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. *Cancer Res.* 46: 4178-4183, 1986.
- A16. Pasanen, M., Vähäkangas, K., Sotaniemi, E.A. and Pelkonen, O.: The effect of cigarette smoking on drug metabolism in the liver and placenta: The use of cotinine in verifying smoking status. *Eur. J. Drug Metab. Pharmacokin.* 13: 41-45, 1988.
- A17. Raunio H, Kojo A, Juvonen R, Honkakoski P, Järvinen P, Lang MA, Vähäkangas K, Gelboin HV, Park S-S, Pelkonen O: Mouse hepatic cytochrome P450 isozyme induction by phenobarbital, pyrazole and 1,4-bis(2-(3,5-dichloropyridyloxy))benzene. *Biochem. Pharmacol.* 37: 4141-4147, 1988.
- A18. Weston, A., Rowe, M., Poirier, M., Trivers, G.E., Vähäkangas, K., Newman, M., Haugen, A., Manchester, D., Mann, D. and Harris C.C.: The application of immunoassays and fluorometry to the detection of polycyclic aromatic hydrocarbon-macromolecular adducts and anti-adduct antibodies in humans. *Int. Arch. Occup. Environ. Health* 60: 157-162, 1988.
- A19. Bjelogrić, N., Iscan, M., Raunio, H., Pelkonen, O. and Vähäkangas, K.: Benzo(a)pyrene-diol-epoxide-DNA adducts and monooxygenase activities in mice treated with benzo(a)pyrene, cigarette smoke or cigarette smoke condensate. *Chem.-Biol. Interactions*, 70: 51-61, 1989.
- A20. Vähäkangas, K., Raunio, H., Pasanen, M., Sivonen, P., Park, S.-S., Gelboin, H. and Pelkonen, O.: Comparison of the formation of benzo(a)pyrene diolepoxide-DNA adducts in rat and human tissues. Evidence for the involvement of cytochrome P450IA1 and P450IA2. *J. Biochem. Toxicol.* 4: 79-86, 1989.
- A21. Pasanen, M., Haaparanta, T., Sundin, M., Sivonen, P., Vähäkangas, K., Raunio, H., Hines, R., Gustafsson, J.-Å. and Pelkonen, O.: Immunochemical and molecular biological studies on human placental cigarette smoke inducible cytochrome P450-dependent monooxygenase activities. *Toxicology* 62: 175-187, 1990.
- A22. Arvela, P., Pelkonen, O., Pyy, L., Sotaniemi, E., Vähäkangas, K. and Yrjänheikki, E.: Antipyrine metabolism in coke oven workers. *Arch. Toxicol. Suppl.* 14: 199-202, 1991.

- A23. Vähäkangas, Trivers, G.E., K., Plummer, S., Hayes R.B., Krokan, H., Rowe, M., Swartz, R.P., Yeager, H.Jr. and Harris, C.C.: O⁶-methylguanine-DNA-methyltransferase and uracil-DNA-glycosylase in human broncho-alveolar lavage cells and peripheral blood mononuclear cells from smokers and non-smokers. *Carcinogenesis* 12: 1389-1394, 1991.
- A24. Bjelogrljic, N. and Vähäkangas, K.: Benzo(a)pyrene-globin adducts detected by synchronous fluorescence spectrophotometry: Method development and relation to lung adducts in mice. *Carcinogenesis* 12: 2205-2209, 1991.
- A25. Vähäkangas KH, Samet JM, Metcalf RM, Welsh JA, Bennett WP, Lane DP and Harris CC: p53 and ras mutations in radon-associated lung cancer from uranium miners. *The Lancet* 339: 576-580, 1992.
- A26. Soini Y, Vähäkangas K, Nuorva K, Kamel D, Lane D, Pääkkö P: p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. *J. Pathol.*, 168: 29-33, 1992.
- A27. Soini Y, Pääkkö P, Nuorva K, Kamel D, Lane D, and Vähäkangas K: Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. *Virchows Archiv. A. Pathol. Anat.* 421: 223-228, 1992.
- A28. Soini Y., Pääkkö P., Alavaikko M., and Vähäkangas K.: p53 expression in lymphatic malignancies. *J. Clin. Pathol.* 45:1011-1014, 1992.
- A29. Soini Y., Kamel D, Nuorva K, Lane DP, Vähäkangas K. and Pääkkö P.: Low p53 protein expression in salivary gland tumors compared with lung carcinomas. *Virchows Archiv A Pathol Anat* 421: 415-420, 1992
- A30. Vähäkangas K, Pyy L and Yrjänheikki E: Assessment of PAH-exposure among coke oven workers. *Pharmacogenetics* 2: 304-308, 1992.
- A31. Kamel D, Pääkkö P., Nuorva K, Vähäkangas K, Soini Y: p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. *J. Pathol.* 170: 67-72, 1993.
- A32. Nuorva K., Soini Y., Kamel D., Autio-Harmainen H., Risteli L., Risteli J., Vähäkangas K. and Pääkkö P.: Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. *Am. J. Pathol.* 142 (No. 3, March): 725-732, 1993
- A33. Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autio-Harmainen H, Risteli J, Risteli L, Nuorva K, Pääkkö P, and Vähäkangas K: p53 Immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. *Br. J. Cancer* 68: 1029-1035, 1993.
- A34. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, Vähäkangas KH, Soini Y, Pääkkö P, Welsh JA, Trump BF, Harris CC: p53 protein accumulates frequently in early bronchial neoplasia. *Cancer Res.* 53: 4817-4822, 1993.

- A35. Salonpää P, Hakkola J, Pasanen M, Pelkonen O, Vähäkangas K, Battula N, Nouso K and Raunio H: Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells. *Eur. J. Pharmacol.* 248: 95-102, 1993.
- A36. Pöllänen R, Soini Y, Vähäkangas K, Pääkkö P and Lehto V-P: Aberrant p53 protein expression in cervical intraepithelial neoplasia. *Histopathology* 23, 1993.
- A37. Bjelogrljic N, Renxiu P, Park SS, Gelboin HV, Honkakoski P, Pelkonen O, Vähäkangas K: Involvement of P450 1A1 in benzo(a)pyrene but not in benzo(a)pyrene-7, 8-dihydrodiol activation by 3-methylcholantrene-induced mouse liver microsomes. *Pharmacol. Toxicol.* 73: 319-324, 1993.
- A38. Bjelogrljic NM, Mäkinen M, Stenbäck F, Vähäkangas K: Benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin. *Carcinogenesis* 15: 771-774, 1994.
- A39. Kamel D, Soini Y, Nuorva K, Khalifa A, Mangoud A, Vähäkangas K, Pääkkö P: p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions. *Virchows Archiv.* 424:349-355, 1994.
- A40. Soini Y, Pääkkö P, Vähäkangas K, Vuopala S, Lehto V-P: Expression of p53 and PCNA in lichen sclerosus et atrophicus with different histological features. *Int. J. Gyn. Pathol.* 13:199-204, 1994.
- A41. Nuorva K, Mäkitaro R, Huhti E, Kamel D, Vähäkangas K, Soini Y, Pääkkö P: p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. *Am. J. Respir. Crit. Care Med.* 150: 528-533, 1994.
- A42. Kamel D, Turpeenniemi-Hujanen T, Vähäkangas K, Pääkkö P, Soini Y: Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. *Histopathology* 25: 339-347, 1994.
- A43. Soini Y, Kamel D, Pääkkö P, Lehto V-P, Oikarinen A and Vähäkangas K: Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. *Br. J. Dermatol.* 131: 514-520, 1994.
- A44. Soini Y, Niemelä A, Kamel D, Herva R, Pääkkö P, Vähäkangas K: P53 immunohistochemical positivity as a prognostic marker in intracranial tumors. *APMIS* 102:786-792, 1994.
- A45. Pienimäki P, Hartikainen A-L, Arvela P, Partanen T, Herva R, Pelkonen O, Vähäkangas K: Carbamazepine and its metabolites in human perfused placenta and in maternal and cord plasma., *Epilepsia* 36:241-248, 1995
- A46. Ala-Kokko T, Pienimäki P, Herva R, Hollmen A., Pelkonen O, Vähäkangas K: Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. *Pharmacol. Toxicol.* 77: 142-148, 1995.
- A47. Rämetsä M, Castren K, Järvinen K, Pekkala K, Turpeenniemi-Hujanen T, Soini Y, Pääkkö P and Vähäkangas K: p53 protein expression is in correlation with benzo(a)pyrene-DNA adducts in carcinoma cell lines. *Carcinogenesis* 16: 2117-2124, 1995.

- A48. Yrjänheikki E, Pyy L, Hakala E, Lapinlampi T and Vähäkangas K: Exposure to polycyclic aromatic hydrocarbons in a modern coking plant. *Am Ind Hyg Assoc J* 56: 782-787, 1995
- A49. Pienimäki P, Fuchs S, Isojärvi J, Vähäkangas K: Improved detection and determination of carbamazepine or oxcarbazepine and their metabolites by high performance liquid chromatography. *J. Chromatogr. B* 673: 97-105, 1995.
- A50. Nuorva K, Soini Y, Kamel D, Pöllänen R, Bloigu R, Vähäkangas K, Pääkkö P: p53 protein accumulation and the presence of human papillomavirus DNA in bronchiolo-alveolar carcinoma correlate with poor prognosis. *Int. J. Cancer (Pred. Oncol.)* 64: 424-429, 1995.
- A51. Törmänen U, Eerola A-K, Rainio P, Vähäkangas K, Soini Y, Sormunen R, Bloigu R, Lehto V-P, and Pääkkö P: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. *Cancer Res.* 55: 5595-5602, 1995.
- A52. Kamel D, Pääkkö P, Pöllänen R, Vähäkangas K, Lehto V-P, Soini Y: Human papillomavirus DNA and an abnormal p53 expression in carcinoma of the urinary bladder. *APMIS* 103: 331-338, 1995.
- A53. Tapiainen T, Järvinen K, Pääkkö P, Bjelogrić N and Vähäkangas K: TPA decreases p53 response to benzo(a)pyrene-DNA adducts in vivo in mouse skin. *Carcinogenesis* 17: 1377-1380, 1996.
- A54. Castren C, Pienimäki P, Arvela P and Vähäkangas K: Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes. *Human Exp. Toxicol.* 15: 577-582, 1996.
- A55. Soini Y, Nuorva K, Kamel D, Pöllänen R, Vähäkangas K, Lehto V-P and Pääkkö P: Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma. *Thorax* 51: 887-893, 1996.
- A56. Kantoniemi A, Vähäkangas K, Oikari A: The capacity of liver microsomes to form benzo(a)pyrene-diolepoxide-DNA adducts and induction of cytochrome P450 1A in feral fish exposed to pulp mill effluents. *Ecotoxicol Environ Safety* 35: 136-141, 1996.
- A57. Ala-Kokko TI, Pienimäki P, Lampela E, Hollmen A, Pelkonen O and Vähäkangas K: Transfer of clonidine and dexmedetomidine across the isolated perfused human placenta. *Acta Anaesthesiol Scand* 41: 313-319, 1997.
- A58. Eerola A-K, Törmänen U, Rainio P, Sormunen R, Bloigu R, Vähäkangas K, Lehto V-P, Soini Y and Pääkkö P: Apoptosis in operated small cell lung carcinoma is inversely related to tumour necrosis and p53 immunoreactivity. *J. Pathol.* 181: 172-177, 1997.
- A59. Pyy L, Mäkelä M, Hakala E, Kakko K, Lapinlampi T, Lisko A, Yrjänheikki E, Vähäkangas K: Ambient and biological monitoring of exposure to polycyclic aromatic hydrocarbons at a coking plant. *The Science and the Total Environment* 199: 151-158, 1997.

- A60. Ala-Kokko TI, Alahuhta S, Jouppila P, Korpi K, Westerling P, Vähäkangas K: The fetomaternal distribution of ropivacaine and bupivacaine after epidural administration for cesarean section. *Int J Obstetr Anesth* 6: 147-152, 1997.
- A61. Pienimäki P, Lampela E, Hakkola J, Arvela P, Raunio H, Vähäkangas K: Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. *Epilepsia* 38(3): 309-316, 1997.
- A62. Welsh JA, Castren K, Vähäkangas K: Single-strand conformation polymorphism analysis to detect p53 mutations: characterization and development of controls. *Clin Chem*. 43: 2251-2255, 1997.
- A63. Ala-Kokko T, Alahuhta S, Arvela P, Vähäkangas K: Maternal, fetal and placental distribution of lidocaine-epinephrine and bupivacaine after epidural administration for cesarean section. *Int J Obst Anesth* 7:82-87, 1998.
- A64. Castren K, Vähäkangas K, Heikkinen E, Ranki AM: Absence of p53 mutations in benign and pre-malignant male genital lesions with over-expressed p53 protein. *Int. J. Cancer* 77: 674-678, 1998.
- A65. Pääkkö P, Rämetsä M, Vähäkangas K, Korpela N, Soini Y, Turunen S, Jaworska M, Gillissen A: Crocidolite asbestos causes an induction of p53 and apoptosis in cultured A-549 lung carcinoma cells. *Apoptosis* 3: 203-212, 1998.
- A66. Myllynen P, Pienimäki P, Raunio H, Vähäkangas K: Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. *Human and Experimental Toxicology*. *Human Exp Toxicol* 17: 668-676, 1998.
- A67. Castren K, Ranki A, Welsh J and Vähäkangas K: Infrequent p53 mutations in arsenic-related skin lesions. *Oncol Res* 10: 475-482, 1998.
- A68. Zheng A, Castren K, Säily M, Savolainen E-R, Koistinen P and Vähäkangas K: p53 status of newly established acute myeloid leukemia cell lines. *Br J Cancer* 79: 407-415, 1999.
- A69. Lampela ES, Nuutinen LH, Ala-Kokko TI, Parikka RM, Laitinen RS, Jouppila PI, Vähäkangas KH: Placental transfer of sulindac, sulindac sulfide and indomethacin in human placental perfusion model. *Am J Obstet Gynecol* 180: 174-180, 1999.
- A70. Hannuksela-Svahn A, Pääkkö P, Autio P, Reunala T, Karvonen J, Vähäkangas K: Expression of p53 protein before and after PUVA treatment in psoriasis. *Acta Derm Venereol (Stockh)* 79: 195-199, 1999
- A71. Huusko P, Castren K, Launonen V, Soini Y, Pääkkönen K, Leisti J, Vähäkangas K, Winqvist R: Germ-line TP53 mutations in Finnish cancer families exhibiting features of

the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2. *Cancer Genetics and Cytogenetics* 112:9-14, 1999

A72. Serpi R, Piispala J, Järvillehto M, Vähäkangas K: Thapsigargin has similar effect on p53 protein response to benzo(a)pyrene-DNA adducts as TPA in mouse skin. *Carcinogenesis* 20: 1755-1760, 1999.

A73. Olivero OA, Parikka R, Poirier MC, Vähäkangas K: 3'-azido-3'-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT: *Mutation Res.* 428: 41-47, 1999.

A74. Bennett WP, Alavanja MCR, Blomeke B, Vähäkangas KH, Castren K, Welsh JA, Bowman ED, Khan MA, Flieder DB, Harris CC: Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. *J Natl Cancer Inst* 91: 2009-2014, 1999.

A75. Zheng A, Mäntymaa P, Säily M, Savolainen E, Vähäkangas K, Koistinen P: P53 pathway is not involved in apoptosis induced by all-trans retinoic acid in acute myeloblastic leukemia cells. *Acta Haematol* 103: 135-143, 2000.

A76. Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, Alavanja MC, Harris CC: p53 and K-ras mutations in lung cancers from former and never-smoking women. *Cancer Res.* 2001 Jun 1;61(11):4350-6.

A77: Rapakko K, Allinen M, Syrjakoski K, Vahteristo P, Huusko P, Vahakangas K, Eerola H, Kainu T, Kallioniemi OP, Nevanlinna H, Winqvist R: Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. *Br J Cancer.* 2001 Jan 5;84(1):116-9.

A78. Hakkola J, Raunio H, Purkunen R, Saarikoski S, Vähäkangas K, Pelkonen O, Edwards, RJ, Boobis A, Pasanen M: Cytochrome P450 3A expression in the human fetal liver. Evidence that CYP3A5 is expressed in only a limited number of fetal livers. *Biol Neonat.* 80: 193-201, 2001.

A79. Myllynen P, Pienimäki P, Jouppila P, Vähäkangas K: Transplacental passage of oxcarbazepine and its metabolites in vivo. *Epilepsia* 42: 1482-1485, 2001.

A80. Heikkilä A, Myllynen P, Keski-Nisula L, Heinonen S, Vähäkangas K, Ylä-Herttuala S: Gene transfer to human placenta ex vivo: A novel application of dual perfusion of human placental cotyledon. *Am J Obstet Gynecol* 186: 1046-51, 2002.

A81. Turpeinen M, Serpi R, Rahkolin M, Vähäkangas K: Comparison of anti-p53 antibodies in immunoblotting. *Biochem Biophys Res Commun* 293: 850-856, 2002

- A82. Knuutinen A, Kallioinen M, Vahakangas K, Oikarinen A.: Smoking and skin: a study of the physical qualities and histology of skin in smokers and non-smokers. *Acta Derm Venereol.* 82: 36-40, 2002.
- A83. Knuutinen A, Kokkonen N, Risteli J, Vahakangas K, Kallioinen M, Salo T, Sorsa T, Oikarinen A.: Smoking affects collagen synthesis and extracellular matrix turnover in human skin. *Br J Dermatol.* 146: 588-594, 2002.
- A84. Myllynen P, Vähäkangas K: An examination of whether human placental perfusion allows accurate prediction of placental diazepam transport. *J Pharmacol Toxicol Methods* 48: 131-138, 2002.
- A85. Myllynen PK, Pienimäki PK, Vähäkangas KH: Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. *Eur J Clin Pharmacol* 58: 677-682, 2003.
- A86. Serpi R, Vähäkangas K: Benzo(a)pyrene-induced changes in p53 and related proteins in mouse skin. *Pharmacol Toxicol* 92: 242-245, 2003
- A87. Loikkanen J, Chvalova K, Naarala J, Vähäkangas KH, Savolainen KM: Pb²⁺-induced toxicity is associated with p53-independent apoptosis and enhanced by glutamate in GT1-7 neurons. *Toxicol Lett.* 144/2: 235-246, 2003
- A88. Loikkanen J, Naarala J, Vähäkangas KH, Savolainen KM: Glutamate increases toxicity of inorganic lead in GT1-7 neurons: Partial protection by flunarizine. *Arch Toxicol* 77: 663-671, 2003
- A89. Loikkanen J, Naarala J, Vähäkangas KH, Savolainen KM: Effect of glutamate and extracellular calcium on uptake of inorganic lead (Pb²⁺) in immortalized mouse hypothalamic GT1-7 neuronal cells. *Toxicol Lett*, 160: 227-232, 2006 [Epub ahead of print Aug 23, 2005]
- A90. Vaskivuo L, Rysä J, Koivuperä J, Myllynen P, Vaskivuo T, Chvalova K, Serpi R, Savolainen E-R, Puistola U, Vähäkangas K: Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. *Toxicol Appl Pharmacol* 216: 89-97, 2006. Epub 2006, May 19
- A91. Stockmann-Juvala H, Naarala J, Loikkanen J, Vähäkangas K, Savolainen K. Fumonisin B1-induced apoptosis in neuroblastoma, glioblastoma and hypothalamic cell lines. *Toxicology* 225: 234-241, 2006.
- A92. Myllynen P, Kurttila T, Vaskivuo L, Vahakangas K. DNA damage caused by benzo(a)pyrene in MCF-7 cells is increased by verapamil, probenecid and PSC833. *Toxicol Lett.* 2007 Feb 28;169(1):3-12.
- A93. Penttinen, P., Tampio, M., Mäki-Paakkanen, J., Vähäkangas, K., Pelkonen, J., Hirvonen, M.-R. DNA damage and p53 in RAW264.7 cells induced by

the spores of co-cultivated *Streptomyces californicus* and *Stachybotrys chartarum*. *Toxicology*, 235: 92-102, 2007.

A94. Tampio M, Loikkanen J, Myllynen P, Mertanen A, Vähäkangas KH. Benzo(a)pyrene increases phosphorylation of p53 at serine 392 in relation to p53 induction and cell death in MCF-7 cells. *Toxicol Lett.* 178: 152-159, 2008

A95. Myllynen P, Kummu T, Kangas T, Ilves M, Immonen E, Rysä J, Pirilä R, Lastumäki A, Vähäkangas K: ABCG2/BCRP modifies the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) in human placenta. *Toxicol Appl Pharmacol* 232: 210-7. 2008, (Jul 18. [Epub ahead of print])

A96. Myllynen P, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vähäkangas KH: Kinetics of gold nanoparticles in the human placenta. *Reprod Toxicol.* 26(2):130-7, 2008 (Jun 28. Epub ahead of print)

A97. Annola K, Karttunen V, Keski-Rahkonen P, Myllynen P, Segerbäck D, Vähäkangas K.: Transplacental transfer of acrylamide and glycidamide are comparable to antipyrine in perfused human placenta. *Toxicol Lett* 182: 50-56, 2008

A98. Annola K, Keski-Rahkonen P, Vähäkangas K, Lehtonen M. Simultaneous determination of acrylamide, its metabolite glycidamide and antipyrine in human placental perfusion fluid and placental tissue by liquid chromatography-electrospray tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci.* 876(2):191-7, 2008 (Nov 5. Epub ahead of print)

A99. Annola K, Heikkinen AT, Partanen H, Woodhouse H, Segerbäck D, Vähäkangas K.: Transplacental transfer of NDMA and DNA adduct formation in perfused human placenta. *Placenta.* 2009, 30: 277-283

A100. Tampio M, Markkanen P, Puttonen K, Hagelberg E, Heikkinen H, Huhtinen K, Loikkanen J, Hirvonen MR, Vähäkangas KH: Induction of PUMA-alpha and down-regulation of PUMA-beta expression is associated with benzo(a)pyrene-induced apoptosis in MCF-7 cells. *Toxicol Lett.* 2009 Aug 10;188(3):214-22.

A101. Immonen E, Serpi R, Vähäkangas K, Myllynen P. Responses of PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) in MCF-7 cells are culture condition dependent. *Chem Biol Interact.* 182: 73-83, 2009 Aug 6. [Epub ahead of print]

A102. Partanen HA, El-Nezami HS, Leppänen J, Myllynen P, Woodhouse H, Vähäkangas KH: Aflatoxin B1 transfer and metabolism in human placenta. *Toxicol. Sci.* 113: 216-225, 2010 (Oct 29. 2009 [Epub ahead of print])

- A103. Myllynen P, Mathiesen L, Weimer M, Annola K, Immonen E, Karttunen V, Kummu M, Mørck TJ, Nielsen JK, Knudsen LE, Vähäkangas KH: Preliminary interlaboratory comparison of the ex vivo dual human placental perfusion system. *Reprod Toxicol*. 30: 94-102, 2010 (Apr 29. [Epub ahead of print])
- A104. Karttunen V, Myllynen P, Prochazka G, Pelkonen O, Segerbäck D, Vähäkangas K: Placental transfer and DNA binding of benzo(a)pyrene in human placental perfusion. *Toxicol Lett*. 197: 75-81, 2010 (May 11. [Epub ahead of print])
- A105. Immonen E, Kummu M, Petsalo A, Pihlaja T, Mathiesen L, Nielsen JKS, Knudsen LE, Vähäkangas K, Myllynen P: Toxicokinetics of the food-toxin IQ in human placental perfusion is not affected by ABCG2 or xenobiotic metabolism. *Placenta*. 31:641-648, 2010
- A106. Halkoaho A, Pietilä A-M, Dumez B, Van Damme K, Heinonen S, Vähäkangas K: Ethical aspects of human placental perfusion: Interview of the mothers donating placenta. *Placenta*. 31: 686-690, 2010
- A107. Peltonen JK, Helppi HM, Pääkkö P, Turpeenniemi-Hujanen T, Vähäkangas KH: p53 in head and neck cancer. Functional consequences and environmental implications of TP53 mutations. *Head & Neck Oncology* 2010 Dec 15;2:36.
- A108. Huovinen M, Loikkanen J, Myllynen P, Vähäkangas KH. Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis. *Toxicol In Vitro* 25: 1007-1017, 2011.
- A109. Peltonen JK, Vahakangas KH, Helppi HM, Bloigu R, Paakko P, Turpeenniemi-Hujanen T. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma : a retrospective archival study. *Head Neck Oncol*. 2011 Apr 22;3(1):20.
- A110. Halkoaho A, Vähäkangas K, Häggman-Laitila A, Pietilä A-M: Views of midwives about ethical aspects of participation in placental perfusion studies. *Midwifery* (2011), doi:10.1016/j.midw.2011.02.003
- A111. Halkoaho A, Pietilä AM, Vähäkangas K. Ethical aspects in placental perfusion studies: Views of the researchers. *Placenta*. 2011 Jul;32(7):511-5. Epub 2011 Apr 27.
- A112. Laatio L, Myllynen P, Serpi R, Rysä J, Ilves M, Lappi-Blanco E, Ruskoaho H, Vähäkangas K, Puistola U. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells. *Tumour Biol*. 32: 985-995 2011.

- A113. Veid J, Karttunen V, Myöhänen K, Myllynen P, Auriola S, Halonen T, Vähäkangas K. Acute effects of ethanol on the transfer of nicotine and two dietary carcinogens in human placental perfusion. *Toxicol Lett.* 205: 257-264, 2011.
- A114. Kotova N, Jurén T, Myöhänen K, Cornelius M, Abramsson-Zetterberg L, Backman J, Menzel U, Rydberg P, Kronberg L, Vähäkangas K, Segerbäck D. (32)P-HPLC analysis of N1-(2-carboxy-2-hydroxyethyl)deoxyadenosine: A DNA adduct of the acrylamide-derived epoxide glycidamide. *Toxicol Lett.* 2011 Nov 10;207(1):18-24.
- A115. Partanen H, Vähäkangas K, Woo CS, Auriola S, Veid J, Chen Y, Myllynen P, El Nezami H. Transplacental transfer of melamine. *Placenta.* 33 (1) : 60-66, 2012.
- A116. Woo CSJ, Partanen H, Myllynen P, Vähäkangas K, El-Nezami H: Fate of the teratogenic and carcinogenic Ochratoxin A in human perfused placenta. *Toxicol Lett.* 208(1): 92-99, 2012
- A117. Mose T, Mathiesen L, Karttunen V, Nielsen JK, Sieppi E, Kumm M, Mørck TA, Myöhänen K, Partanen H, Vähäkangas K, Knudsen LE, Myllynen P. Meta-analysis of data from human ex vivo placental perfusion studies on genotoxic and immunotoxic agents within the integrated European project NewGeneris. *Placenta.* 2012 May;33(5):433-439, 2012.
- A118. Vehniäinen ER, Vähäkangas K, Oikari A. UV-B exposure causes DNA damage and changes in protein expression in northern pike (*Esox lucius*) posthatched embryos. *Photochem Photobiol.* 88(2): 363-370, 2012.
- A119. Pesonen M, Pasanen M, Loikkanen J, Naukkarinen A, Hemmilä M, Seulanto H, Kuitunen T, Vähäkangas K. Chloropicrin induces endoplasmic reticulum stress in human retinal pigment epithelial cells. *Toxicol Lett.* 211(3): 239-245, 2012.
- A120. Taga M, Mechanic LE, Hagiwara N, Vähäkangas KH, Bennett WP, Alavanja MC, Welsh JA, Khan MA, Lee A, Diasio R, Edell E, Bungum A, Jang JS, Yang P, Jen J, Harris CC. EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women. *Cancer Epidemiol Biomarkers Prev.* 21(6): 988-992, 2012.
- A121. Halkoaho A, Pietilä AM, Vesalainen M, Vähäkangas K Ethical aspects in tissue research: thematic analysis of ethical statements to the research ethics committee. *BMC Med Ethics.* 8: 13:20, 2012.
- A122. Kumm M, Sieppi E, Wallin K, Rautio A, Vähäkangas K, Myllynen P. Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2. *Placenta.* 33(10): 859-865, 2012.
- A123. Abass K, Huusko A, Nieminen P, Myllynen P, Pelkonen O, Vahakangas K, Rautio A. Estimation of health risk by using toxicokinetic modelling: A case study of polychlorinated biphenyl PCB153. *J Hazard Mater.* 261C: 1-10, 2013.

- A124. Pesonen M, Häkkinen M, Rilla K, Juvonen R, Kuitunen T, Pasanen M, Vähäkangas K. Chloropicrin-induced toxic responses in human lung epithelial cells. *Toxicol Lett.* 2014 226: 236-244, 2014.
- A125. Repo JK, Pesonen M, Mannelli C, Vähäkangas K, Loikkanen J. Exposure to ethanol and nicotine induces stress responses in human placental BeWo cells. *Toxicol Lett* 224: 264-271, 2014.
- A126. Robles AI, Yang P, Jen J, McClary AC, Calhoun K, Bowman ED, Vähäkangas K, Greathouse KL, Wang Y, Olivo-Marston S, Wenzlaff AS, Deng B, Schwartz AG, Ryan BM. A DRD1 Polymorphism Predisposes to Lung Cancer among Those Exposed to Secondhand Smoke during Childhood. *Cancer Prev Res (Phila).* 7: 1210, 2014
- A127. Halme M, Pesonen M, Hakala U, Pasanen M, Vähäkangas K, Vanninen P. Applying human and pig hepatic *in vitro* experiments for sulfur mustard study: Screening and identification of metabolites by liquid chromatography/tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* 2015, 29, 1279-1287.
- A128. Soininen SK, Repo JK, Karttunen V, Auriola S, Vähäkangas KH, Ruponen M: Human placental cell and tissue uptake of doxorubicin and its liposomal formulations. *Toxicol Lett.* 2015, 239: 108-114, doi: 10.1016/j.toxlet.2015.09.011.
- A129. Halme M, Pesonen M, Grandell T, Kuula M, Pasanen M, Vähäkangas K, Vanninen P. Analysis of nitromethane from samples exposed *in vitro* to chloropicrin by stable isotope dilution headspace gas chromatography with mass spectrometry. *J Sep Sci.* 2015, 38: 3383-3389. doi: 10.1002/jssc.201500457. [Epub ahead of print]
- A130. Huovinen M, Loikkanen J, Naarala J, Vähäkangas K. Toxicity of diuron in human cancer cells. *Toxicol In Vitro.* 2015 Oct;29(7):1577-86. doi: 10.1016/j.tiv.2015.06.013. Epub 2015 Jun 15.
- A131. Karttunen V, Sahlman H, Repo JK, Woo CS, Myöhänen K, Myllynen P, Vähäkangas KH. Criteria and challenges of the human placental perfusion - Data from a large series of perfusions. *Toxicol In Vitro.* 2015 Oct;29(7):1482-91. doi: 10.1016/j.tiv.2015.06.001. Epub 2015 Jun 6.
- A132. Kummu M, Sieppi E, Koponen J, Laatio L, Vähäkangas K, Kiviranta H, Rautio A, Myllynen P. Organic anion transporter 4 (OAT 4) modifies placental transfer of perfluorinated alkyl acids PFOS and PFOA in human placental *ex vivo* perfusion system. *Placenta.* 2015 Oct;36(10):1185-91
- A133. Pesonen M, Storvik M, Kokkola T, Rysä J, Vähäkangas K, Pasanen M. Transcriptomic Analysis of Human Primary Bronchial Epithelial Cells after Chloropicrin Treatment. *Chem Res Toxicol.* 2015 Oct 19;28(10):1926-35.

- A134. Nieminen P, Abass K, Vähäkangas K, Rautio A: Statistically non-significant papers in environmental health studies included more outcome variables. *Biomed Environ Sci* 28(9): 666-673, 2015
- A135. Halme M, Pesonen M, Salo H, Söderström M, Pasanen M, Vähäkangas K, Vanninen P. Comparison of in vitro metabolism and cytotoxicity of capsaicin and dihydrocapsaicin. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2016 Jan 15;1009-1010:17-24.
- A136. Sieppi E, Vähäkangas K, Rautio A, Ietta F, Paulesu L, Myllynen P. The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures. *Mol Cell Mol Cell Endocrinol.* 2016 Jul 5;429:41-49
- A137. Rumrich IK, Viluksela M, Vähäkangas K, Gissler M, Surcel HM, Hänninen O. Maternal Smoking and the Risk of Cancer in Early Life - A Meta-Analysis. *PLoS One.* 2016 Nov 8;11(11):e0165040
- A138. Pesonen M, Rysä J, Storvik M, Rilla K, Pasanen M, Vähäkangas K. Molecular targets of chloropicrin in human airway epithelial cells. *Toxicol In Vitro.* 2017 Aug;42:247-254
- A139. Rumrich IK, Vähäkangas K, Viluksela M, Gissler M, Surcel H-M, de Ruyter H, Jokinen J, Hänninen O. The MATEX cohort – a Finnish population register birth cohort to study health effects of prenatal exposures. *BMC Public Health.* 2017 Nov 7;17(1):871
- A140. Abass K, Huusko A, Knutsen HK, Nieminen P, Myllynen P, Meltzer HM, Vähäkangas K, Rautio A. Quantitative estimation of mercury intake by toxicokinetic modelling based on total mercury levels in humans. *Environ Int.* 2018, 114:1-11
- A141. Mohammed AM, Karttunen V, Huuskonen P, Huovinen M, Auriola S, Vähäkangas K: Transplacental transfer and metabolism of diuron in human placenta. *Toxicol Lett* 2018, 295: 307-313.
- A142. Huuskonen P, Keski-Nisula L, Heinonen S, Voutilainen S, Tuomainen TP, Pekkanen J, Lampi J, Lehto SM, Haaparanta H, Elomaa AP, Voutilainen R, Backman K, Kokki H, Kumpulainen K, Paananen J, Vähäkangas K, Pasanen M. Kuopio birth cohort - design of a Finnish joint research effort for identification of environmental and lifestyle risk factors for the wellbeing of the mother and the newborn child. *BMC Pregnancy Childbirth.* 2018 Sep 21;18(1):381

IN PRESS

- A143. Rumrich IK, Vähäkangas K, Viluksela M, Gissler M, Surcel H-M, Korhonen A, de Ruyter H, Hänninen O: Smoking during pregnancy in Finland - Trends in the MATEX cohort" Accepted, *Scand J Public Health.* 2018, October 17

B. REVIEWS IN PEER-REVIEWED JOURNALS

- B1. Pelkonen, O., Vähäkangas, K. and Nebert, D.W.: Binding of polycyclic aromatic hydrocarbons to DNA: comparison with mutagenesis and tumorigenesis. *J. Toxicol. Environ. Health* 6: 1009(89)-1020(100), 1980.
- B2. Pelkonen, O. and Vähäkangas, K.: Metabolic activation and inactivation of chemical carcinogens. *J. Toxicol. Environ. Health* 6: 989(69)-999(79), 1980.
- B3. Pelkonen, O., Vähäkangas, K., Kärki, N.T. and Sotaniemi, E.A.: Genetic and environmental regulation of aryl hydrocarbon hydroxylase in man: Studies with liver, lung, placenta and lymphocytes. *Toxicol. Pathol.* 12: 19-23, 1984.
- B4. Autrup, H., Grafström, R., Vähäkangas, K. and Harris, C.C.: Interindividual variations in carcinogen metabolism. *Arch. Toxicol., Suppl.* 9. 147-153, 1986.
- B5. Ala-Kokko T, Vähäkangas K, Pelkonen O: Placental function and principles of drug transfer. *Acta Anaesthesiol Scand* 37 (S100):47-49, 1993.
- B6. Hainaut P and Vähäkangas K: P53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. *Pathologie-Biologie* 45: 833-844, 1997.
- B7. Bennett WP, Hussain SP, Vähäkangas KH, Khan MA, Shields PG, Harris CC: Molecular epidemiology of human cancer risk: Gene-environment interactions and p53 mutation spectrum in human lung cancer. *J Pathol* 187: 8-18, 1999
- B8. Ala-Kokko TI, Myllynen P, Vähäkangas K: Ex vivo perfusion of the human placental cotyledon: implications for anesthetic pharmacology. *Int J Obstet Anesth* 9:26-38, 2000
- B9. Vähäkangas KH: Ethical implications of genetic analysis of individual susceptibility to diseases. *Mutat Res.* 482: 105-110, 2001
- B10. Vähäkangas K: TP53 mutations in workers exposed to occupational carcinogens. *Hum Mutat.* 21:240-51, 2003.
- B11. Vähäkangas K: Ethical aspects of molecular epidemiology of cancer. *Carcinogenesis* 25: 465-71, 2004. Epub 2003 Dec 04. 2004
- B12. Van Larebeke NA, Birnbaum LS, Boogaerts MA, Bracke M, Davis DL, Demarini DM, Hooper K, Huff J, Kleinjans JC, Legator MS, Schoeters G, Vahakangas K.: Unrecognized or potential risk factors for childhood cancer. *Int J Occup Environ Health.* 11:199-201, 2005.
- B13. Myllynen P, Pienimäki P, Vahakangas K. Human placental perfusion method in the assessment of transplacental passage of antiepileptic drugs. *Toxicol Appl Pharmacol.* 207: S489-S494, 2005.

- B14. Vähäkangas K, Myllynen P: Experimental methods to study human transplacental exposure to genotoxic agents. *Mutat Res* 608: 129-135, 2006
- B15. Peltonen J, Welsh JA, Vähäkangas KH: Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene. *Hum Exp Toxicol* 26: 9-18, 2007.
- B16. Myllynen P, Pasanen M, Vahakangas K. The fate and effects of xenobiotics in human placenta. *Expert Opin Drug Metab Toxicol.* 3: 331-346, 2007.
- B17. Merlo D, Knudsen L, Matusiewicz K, Niebroj L, Vähäkangas K: Ethics in studies on children and environmental health. *J Med Ethics* 33: 408-413, 2007
- B18. Bremer S, Brittebo E, Dencker L, Knudsen LE, Mathiesen L, Olovsson M, Pazos P, Pellizzer C, Paulseu LR, Schaefer W, Swarcz M, Staud F, Stavreus-Evers A, Vähäkangas K: In vitro tests for detecting chemicals affecting the embryo implantation process. *ATLA* 35: 421-439, 2007.
- B19. Merlo DF, Vahakangas K, Knudsen LE. Scientific integrity: critical issues in environmental health research. *Environ Health.* 2008 Jun 5;7 (Suppl 1):S9
- B20. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas K, Samet JM: Lung cancer in never smokers: Molecular profiles and therapeutic implications. *Clin Cancer Res* 15: 5646-5661, 2009
- B21. Vähäkangas K, Myllynen P: Drug transporters in the human blood-placental barrier. *Br J Pharmacol.* 2009 Oct;158(3):665-78. Epub 2009 Sep 25.
- B22. Myllynen P, Immonen E, Kumm M, Vähäkangas K: Developmental expression of drug metabolizing enzymes and transporter proteins in human fetoplacental unit. *Expert Opin Drug Metab Toxicol.* 2009 Dec;5(12):1483-99.
- B23. Pesonen M, Vähäkangas K, Halme M, Vanninen P, Seulanto H, Hemmilä M, Pasanen M, Kuitunen T: Capsaicinoids, chloropicrin and sulfur mustard: Possibilities for exposure biomarkers. *Frontiers in Pharmacology/Predictive Toxicology.* Dec 2010, Vol. 1, Article 140, doi: 10.3389/fphar.2010.00140
- B24. Myöhänen Kirsi, Vähäkangas Kirsi (OBS! in PubMed under Kirsi M & Kirsi V). Fetal exposure to food and environmental carcinogens in human beings. *Basic Clin Pharmacol Toxicol* 2011, Jul 10. doi: 10.1111/j.1742-7843.2011.00761.x. [Epub ahead of print]
- B25. Vähäkangas K. Chemical exposure as etiology in developmental origin of adult onset human cancer. *Front Pharmacol.* 2:62, 2011.

- B26. Pelkonen O, Turpeinen M, Hakkola J, Abass K, Pasanen M, Raunio H, Vähäkangas K. Preservation, induction or incorporation of metabolism into the in vitro cellular system - Views to current opportunities and limitations. *Toxicol In Vitro*. 27(5):1578-1583, 2013.
- B27. Myllynen P, Vähäkangas K. Placental transfer and metabolism: an overview of the experimental models utilizing human placental tissue. *Toxicol In Vitro*. 27(1): 507-512, 2013.
- B28. Nieminen P, Lehtiniemi H, Huusko A, Vähäkangas K, Rautio A. Polychlorinated biphenyls (PCBs) in relation to secondary sex ratio--a systematic review of published studies. *Chemosphere*. 91(2): 131-138, 2013.
- B29. Vähäkangas K. Research ethics in the post-genomic era. *Environ Mol Mutagen*. 54: 599-610, 2013.
- B30. Pesonen M, Vähäkangas K.: Autophagy in exposure to environmental chemicals. *Toxicol Lett*, 2019 Jan 19;305:1-9.

C. ARTICLES AND CHAPTERS IN BOOKS AND OTHER PUBLICATIONS

- C1. Vähäkangas, K., Nevasaari, K., Pelkonen, O. and Kärki, N.T.: The disposition of benzo(a)pyrene in isolated perfused rat lung. In Ullrich, V. (Ed.) *Microsomes and Drug Oxidations*. Pergamon Press, Oxford, 1977, pp. 453-458.
- C2. Vähäkangas, K., Nevasaari, K., Pelkonen, O. and Kärki, N.T.: Effects of inhibition of various pathways in benzo(a)pyrene metabolism in isolated perfused lung. *Excerpta Medica International Congress Series No 440. Industrial and Environmental Xenobiotics* (Fouts R, ed.). Proceedings of an International Conference, Prague, Czechoslovakia, 13-15 September 1977. Elsevier North-Holland Biomedical Press, Amsterdam 1978, pp. 59-61.
- C3. Pelkonen, O., Vähäkangas, K. and Kärki, N.T.: Genetic and environmental regulation of aryl hydrocarbon hydroxylase in the placenta. In Gustafsson, J.-A., Carlstedt-Duke, J., Mode, A. and Rafter, J. (Eds.) *Biochemistry, Biophysics and Regulation of Cytochrome P-450*. Elsevier North-Holland Biomedical Press, Amsterdam, 1980, pp. 163-170.
- C4. Vähäkangas, K.: Lung perfusion studies on benzo(a)pyrene metabolism. A thesis. *Acta Universitatis Ouluensis, Series D, Medica No. 77, Pharmacologica et Physiologica No. 13*. Oulu, Finland, 1981.
- C5.. Vähäkangas, K., Autrup, H. and Harris, C.C.: Interindividual variation in carcinogen metabolism, DNA damage and DNA repair. In Berlin, A., Draper, M., Hemminki, K. and Vainio, H. (Eds.) *Monitoring Human Exposure to Carcinogenic and Mutagenic Agents*. IARC Scientific Publications No. 59. IARC, Lyon, 1984, pp. 85-98.
- C6. Harris, C.C., Autrup, H., Vähäkangas, K. and Trump, B.F.: Interindividual variation in carcinogen activation and DNA repair. In Omenn, G.S., Gelboin, H.V. (Eds.) *Genetic Variability in Responses to Chemical Exposure, Banbury Report No. 16*. Cold Spring Harbor Laboratory, Cold Spring Harbor, 1984, pp. 145-151.
- C7. Pelkonen, O., Pasanen, M., Vähäkangas, K. and Sotaniemi, E.A.: Multiple forms of human hepatic cytochrome P-450. In Vereczkey, L. and Magyar, K. (Eds.) *Cytochrome P-450 Biochemistry, Biophysics and Induction*. Akademiai Kiado, Budapest, 1985, pp. 247-251.
- C8. Harris, C.C., Vähäkangas, K., Autrup, H., Trivers, G.E., Shamsuddin, A.K.M., Trump, B.F., Boman, B.B. and Mann, D.L.: Biochemical and molecular epidemiology of human cancer risk. In Scarpelli, D. and Craighead, J. (Eds.) *The Pathologist and Environment*. Monogr Pathol. 26. Williams and Wilkins, Baltimore 1985, pp. 140-167.
- C9. Vähäkangas, K. and Pelkonen, O.: Host variations in carcinogen metabolism and DNA repair. In Muller and Weber (Eds.) *Familial Cancer*. Karger, Basel 1985, pp. 238-241.
- C10. Vähäkangas, K., Pasanen, M., Sotaniemi, E. and Pelkonen, O.: Drug metabolism in man: Life style factors: Smoking and alcohol. In: *Enzyme Induction in Man* (eds. E.A. Sotaniemi and O. Pelkonen) Taylor & Francis Ltd., London 1987, pp. 189-198.

- C11. Vähäkangas, K., Arvela, P. and Pelkonen, O. (eds.): Annual Symposium of the Finnish Society of Toxicology. Program and abstracts. Acta Universitatis Ouluensis, Series D, Medica no. 157, University of Oulu, Oulu, Finland 1987.
- C12. Pelkonen, O., Pasanen, M. and Vähäkangas, K.: Metabolic activation by the fetus and placenta. In Benford, D.J., Bridges, J.W. and Gibson, G.G. (eds.) Drug Metabolism - from Molecules to Man. Taylor and Francis, London 1987, pp. 734-746.
- C13. Weston, A., Trivers, G., Vähäkangas, K., Newman, M., Rowe, M., Mann, D., Harris, C.C.: Detection of carcinogen-DNA adducts in human cells and antibodies to these adducts in human sera. In: Progress in Experimental Tumor Research, vol. 31 (Homburger, F., ed.), Karger, Basel 1987, pp. 76-85.
- C14. Weston, A., Newman, M., Vähäkangas, K., Rowe, M., Trivers, G.E., Mann, D.L. and Harris, C.C.: Measurement of carcinogen-macromolecular adducts and serum antibodies recognizing DNA adducts in biological specimens from people exposed to chemical carcinogens. In: Short term bioassays in the analysis of complex environmental mixtures V (Sandhu, DeMarini, Mass, Moore and Mumford, eds.) pp. 91-102, Plenum Press, New York 1987.
- C15. Haugen, Å., Becher, G., Benestad, C., Vähäkangas, K., Trivers, G.E., Newman, M., Harris, C.C.: Biomonitoring of individuals exposed to high levels of PAH in the work environment. In: Polynuclear Aromatic Hydrocarbons: A Decade of Progress (Cooke, M. & Dennis, A.J., eds.) pp. 377-391, Battelle Press, Ohio 1988.
- C16. Vähäkangas, K., Bjelogrić, N., Sivonen, P., Kärki, N., and Pelkonen, O.: The formation of benzo(a)pyrene diolepoxide DNA-adducts in human tissues. In: Cytochrome P-450: Biochemistry and Biophysics (I. Schuster, ed.) Taylor & Francis, Basingstoke, Hampshire, Great Britain 1989. pp. 775-777. (Proceedings of the 6th International Conference on Biochemistry and Biophysics of Cytochrome P-450, Vienna, Austria, July 3-8, 1988.)
- C17. Vähäkangas, K., Pelkonen, O. and Harris, C.C.: Synchronous fluorescence spectrophotometry of BPDE-DNA adducts - A tool for detection of in vitro and in vivo-developed DNA-damage by benzo(a)pyrene exposure. In Bartsch, H., Hemminki, K. and O'Neill, I.K. (eds.) Methods for Detecting DNA-damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention. IARC, Lyon 1988, pp. 208-212.
- C18. Vähäkangas K, Pelkonen O: Host variations in carcinogen metabolism and DNA-repair. In: Genetic Epidemiology of Cancer (eds. H.T. Lynch & J. Hirayama) CRC Press Inc., Boca, Raton, Florida, USA, 1989, pp. 35-54.
- C19. Pelkonen O, Pasanen M, Raunio H and Vähäkangas K: Immunological and molecular biological studies of P450 isozymes in human fetus and placenta. An extended abstract. VIIth Symposium on Developmental Pharmacology. Reihradsburg Castle, May 2-5, 1989, Universitätsverlag Jena, pp. 17-22.
- C20. Vähäkangas, K. and Pelkonen, O.: Biochemische Untersuchungsverfahren zur Kontrolle des Nictrauchens: Bewertung der Brauchbarkeit biochemischer Indikatoren der Exposition gegen Zigarettenrauch (Non smoking control by biochemical investigations: Assessment of usefulness of biochemical indices of cigarette smoke exposure) Z.ärztl.

Fortbild. 83: 1061-1064, 1989. (Proceedings of the 2 gemeinsames SYMPOSIUM der AG "Förderung des Nichtrauchens". Reinhardtsbrunn, DDR, 2-4.11.1988).

C21. Vähäkangas, K. and Yrjänheikki, E.: Synchronous fluorescence spectrophotometry of benzo(a)pyrene diolepoxide-DNA adducts in workers exposed to polycyclic aromatic hydrocarbons. In: Complex mixtures and cancer risk (Ed. H. Vainio, M. Sorsa and A.J. McMichael) IARC Scientific Publications No. 104, IARC, Lyon 1990, pp. 199-204.

C22. Vähäkangas K and Pelkonen O: Extrahepatic metabolism of nicotine and related compounds by cytochromes P450. In: Pharmacokinetics and metabolism of nicotine and other tobacco alkaloids (J. Gorrod, S. Schwartz and J. Wahren, eds.), Chapman & Hall, London, 1993, pp. 121-137.

C23. Vähäkangas K: Achievements and perspectives in the molecular epidemiology of carcinogenesis. In: Molecular Mechanisms in Radiation Mutagenesis and Carcinogenesis (Eds. Chadwick KH, Cox R, Leenhouts HP, Thacker J). Report EUR 15294, European Commission, Brussels 1994, pp. 279-288.

C24. Ala-Kokko T and Vähäkangas K: Transplacental transfer: implications for the anesthesiologist. - ESA, European Society of Anesthesiologists, 5th annual meeting, Lausanne 3-6 May 1997. Refresher Course Lectures, pp. 151-154.

C25. Hainaut P and Vähäkangas K: Genetic analysis of metabolic polymorphisms in molecular epidemiological studies: social and ethical implications. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P, eds., Metabolic Polymorphisms and Cancer, IARC Scientific Publications, IARC, Lyon, France 1999, pp. 395-402.

C26. Vähäkangas KH, Castren K, Welsh JA: Single-strand conformation polymorphism analysis of mutations in exons 4-8 of the TP53 gene. In: Methods in Molecular Medicine, vol 49: Molecular Pathology Protocols (Ed. Killeen AA). Humana Press Inc., Totowa, NJ. 2000, pp. 15-27 (invited paper)

C27. Vähäkangas K: Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. *Method Mol Med* 74: 43-59, 2003.

C28. Pelkonen O, Vähäkangas K, Raunio H: Xenobiotic metabolism and cancer susceptibility. In: Handbook of Experimental Pharmacology Vol 156: Mechanisms in Carcinogenesis and Cancer prevention (ed. Vainio H, Hietanen E), pp 253-269, 2003.

C29. Pelkonen O, Vähäkangas K, Rautio A, Raunio H: Pharmacogenomics of carcinogen-metabolizing enzymes and Cancer Susceptibility. In: From Molecular Targets to Public Health (ed. K Husgafvel-Pursiainen, H Vainio). People and Work – Research Reports 59, FIOH, Helsinki 2003, pp. 61-74

C30. Hakkarainen J, Welsh J, Vähäkangas K: TP53 mutation detection by SSCP and sequencing. *Methods Mol Med* 97: 191-208, 2004 (Molecular Diagnosis of Cancer, Bartlett & Roulston, eds., Humana Press 2004).

C31. Husgafvel-Pursiainen K, Savolainen K, Rautio A, Sorsa M, Tähti H, Ylitalo P, Vähäkangas K: Editorial. Special Issue: The Proceedings of the 10th International Congress of Toxicology, Tampere, Finland, July 11-15, 2004. Living in a safe chemical world. *Toxicol Appl Pharmacol* 207: S1, 2005.

C32. Pelkonen O, Vähäkangas K, Gupta RC: Placental toxicity of organophosphate and carbamate pesticides. Chapter 33. In *Toxicology of Organophosphate & Carbamate Compounds 2006*, pp. 463-479.

C33. Bremer S¹, Brittebo E, Dencker L, Knudsen LE, Mathisien L, Olovsson M, Pazos P, Pellizzer C, Paulesu LR, Schaefer W, Schwarz M, Staud F, Stavreus-Evers A, Vähäkangas K. In vitro tests for detecting chemicals affecting the embryo implantation process. The report and recommendations of ECVAM workshop 62 -- a strategic workshop of the EU ReProTect project. *Altern Lab Anim.* 2007 Aug;35(4):421-39.

C34. Vähäkangas K: Molecular epidemiology and ethics. Biomarkers of disease susceptibility. In (Wild, Vineis & Garte eds.) *Molecular Epidemiology of Chronic Diseases*. John Wiley & Sons, Ltd., 2008, pp. 279-295.

C35. Vähäkangas KH, Veid J, Karttunen V, Partanen, H, Sieppi E, Kummu M, Myllynen P, MD, Loikkanen J: The significance of ABC transporters in human placenta for the exposure of fetus to xenobiotics. Chapter 79 In: *Reproductive and developmental toxicology* (ed. Ramesh C. Gupta), Elsevier Inc. 2011, pp. 1051-1065.

C36. Heinonen T, Tähti H, Vähäkangas K, Blaauboer BJ. Editorial. Towards toxicity assessment without animals: 28th workshop of SSCT and FINCOPA seminar 21-23 September 2011, Tampere, Finland. *Toxicol In Vitro.* 27(5): 1563-1564, 2013.

C37. Vähäkangas K, Loikkanen J, Sahlman H, Karttunen V, Repo J, Sieppi E, Kummu M, Huuskonen P, Myöhänen K, Storvik M, Pasanen M, Myllynen P, Pelkonen O: Biomarkers of toxicity in human placenta. Chapter 20 in Gupta (ed) *Biomarkers of Toxicity*, Academic Press, Elsevier Inc., USA, 2014, pp.325-360.

C38. Vähäkangas K, Repo J, Ietta F, Mannelli C, Paulesu LR: Reproductive safety of food: Studies on fetal exposure using human placental models. In (Peltola, Päällysaho & Uusimäki eds.) *Proceedings of the ERIAFF conference Sustainable Food Systems: Multi-actor Co-operation to Foster New Competitiveness of Europe*. Publications of Seinäjoki University of Applied Sciences B. Reports 81, Seinäjoki 2014, pp. 11-21.

C39. Karttunen V, Mohammed AM, Vähäkangas KH. The significance of ABC transporters in human placenta for the exposure of fetus to xenobiotics. Chapter 67, In: *Reproductive and developmental toxicology*, (Vol II, ed. Dr. Ramesh Gupta), Academic Press, Elsevier 2017, pp. 1275-1300.

C40. Vähäkangas K, Loikkanen J, Sahlman H, Karttunen V, Repo J, Sieppi E, Kummu M, Huuskonen P, Myöhänen K, Storvik M, Pasanen M, Myllynen P, Pelkonen O: Biomarkers of toxicity in human placenta. Chapter 18 in Gupta (ed) Biomarkers of Toxicity, Second Edition, Academic Press, Elsevier Inc., USA, 2019, pp.303-339.